Establishment Labs Holdings Inc. (NASDAQ:ESTA) Short Interest Up 21.3% in April

Establishment Labs Holdings Inc. (NASDAQ:ESTAGet Rating) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 987,000 shares, a growth of 21.3% from the April 15th total of 813,400 shares. Based on an average daily volume of 191,400 shares, the days-to-cover ratio is currently 5.2 days. Approximately 4.8% of the company’s shares are sold short.

Several equities analysts have commented on ESTA shares. Zacks Investment Research raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a research report on Tuesday, May 10th. The Goldman Sachs Group decreased their price target on shares of Establishment Labs from $78.00 to $67.00 and set a “neutral” rating for the company in a research report on Monday, March 21st. Cowen raised their price objective on shares of Establishment Labs from $95.00 to $125.00 in a report on Friday, April 22nd. Cowen raised their price objective on shares of Establishment Labs from $95.00 to $125.00 in a report on Friday, April 22nd. Finally, BTIG Research raised their price objective on shares of Establishment Labs from $95.00 to $110.00 and gave the company a “buy” rating in a report on Friday, April 22nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Establishment Labs currently has an average rating of “Buy” and an average price target of $98.86.

Shares of ESTA traded down $2.20 during midday trading on Wednesday, reaching $58.75. The stock had a trading volume of 2,287 shares, compared to its average volume of 322,485. The company’s fifty day simple moving average is $66.37 and its two-hundred day simple moving average is $63.45. Establishment Labs has a 1-year low of $46.93 and a 1-year high of $93.80. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.01 and a quick ratio of 2.23.

Establishment Labs (NASDAQ:ESTAGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.18. Establishment Labs had a negative net margin of 29.77% and a negative return on equity of 70.10%. During the same quarter last year, the company posted ($0.29) EPS. Equities analysts forecast that Establishment Labs will post -1.31 EPS for the current fiscal year.

In other news, major shareholder Jw Asset Management, Llc bought 5,000 shares of Establishment Labs stock in a transaction on Wednesday, March 2nd. The shares were bought at an average cost of $59.45 per share, with a total value of $297,250.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders purchased 75,000 shares of company stock valued at $4,717,450 in the last three months. 13.08% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC raised its stake in Establishment Labs by 187.7% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 53,800 shares of the company’s stock worth $3,851,000 after acquiring an additional 35,100 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Establishment Labs by 5.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 97,989 shares of the company’s stock worth $7,014,000 after purchasing an additional 5,005 shares during the last quarter. Bamco Inc. NY grew its position in Establishment Labs by 71.3% during the 3rd quarter. Bamco Inc. NY now owns 36,152 shares of the company’s stock worth $2,588,000 after purchasing an additional 15,052 shares during the last quarter. NorthRock Partners LLC grew its position in Establishment Labs by 973.3% during the 3rd quarter. NorthRock Partners LLC now owns 42,931 shares of the company’s stock worth $3,073,000 after purchasing an additional 38,931 shares during the last quarter. Finally, New York State Common Retirement Fund grew its position in Establishment Labs by 212.6% during the 3rd quarter. New York State Common Retirement Fund now owns 9,455 shares of the company’s stock worth $677,000 after purchasing an additional 6,430 shares during the last quarter. Hedge funds and other institutional investors own 77.79% of the company’s stock.

About Establishment Labs (Get Rating)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.

Read More

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.